Zobrazeno 1 - 10
of 94
pro vyhledávání: ''
Autor:
Yiping Wu, Lei Yang, Xin Li, Jin Ye, Jia Cong, Na Yao, Liqiang Wei, Xueying Cui, Jing Ding, Jingwen Wang, Jing Yang
Publikováno v:
Leukemialymphoma. 61(12)
We retrospectively analyzed the treatment outcomes of elderly patients (aged ≥ 60 years) with extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) and investigated the prognostic factors. Fifty-two elderly patients received chemotherapy al
Autor:
Francesco Merli, Luca Nassi, Monica Tani, Flavia Salvi, Vincenzo Pavone, Marco Ladetto, Manuela Zanni, Annalisa Peli, Stefano Volpetti, Riccardo Centurioni, Stefano Luminari, Annalisa Arcari, Alessandro Re, Michele Spina, Alessandro Pulsoni, Andrea Evangelista, Anna Marina Liberati, Alessandra Tucci, Roberto Freilone, Gerardo Musuraca, Caterina Patti, Caterina Stelitano, Stefania Massidda
Publikováno v:
Leukemialymphoma. 60(12)
This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I-IIA and IIB-IV
Autor:
Nathan Fowler, Sweet Ping Ng, Bouthaina S. Dabaja, Jillian R. Gunther, Sarah A. Milgrom, Zeina Ayoub, T.Y. Andraos, Chelsea C. Pinnix, Felipe Samaniego, Luis Fayad, Sattva S. Neelapu, Loretta J. Nastoupil
Publikováno v:
Leukemialymphoma. 60(13)
Patients with early-stage nodal follicular lymphoma (FL) may be rendered free of detectable disease by a diagnostic excisional biopsy. We reviewed the management and outcomes of 48 patients with FL, diagnosed from 2003-2013, treated at a single insti
Autor:
Jennifer R. Brown, Philip C. Amrein, Philippe Armand, Jacob D. Soumerai, Lillian Werner, Ephraim P. Hochberg, Jeremy S. Abramson, Donna Neuberg, David C. Fisher, Matthew S. Davids
Publikováno v:
Leukemialymphoma. 60(12)
Bendamustine-rituximab (BR) is a standard therapy in CLL, and lenalidomide has single-agent activity. This phase 1 study evaluated lenalidomide-BR as initial CLL therapy. Thirteen patients were treated at three dose levels (DL), and an additional 10
Publikováno v:
Leukemialymphoma. 60(5)
Elderly patients with classical Hodgkin lymphoma (cHL) are understudied and poorly defined. The National Cancer Data Base was queried for adults with cHL diagnosed 2004-2013: 22,547 age 18-39, 12,841 age 40-59, and 10,873 age ≥60 were identified. T
Autor:
Yoshikazu Ito, Naoya Nakamura, Tetsuzo Tauchi, Seiichiro Katagiri, Yuko Tanaka, Hiroaki Fujimoto, Seiichi Okabe, Junko H. Ohyashiki, Chiaki Kawana, Seiichiro Yoshizawa, Kazuma Ohyashiki, Tomohiro Umezu, Tamiko Suguro, Michiyo Asano, Daigo Akahane, Yuu Saito, Kenichi Tadokoro, Moritaka Gotoh
Publikováno v:
Leukemialymphoma. 60(5)
Deletion polymorphism of BCL-2-like protein 11 (BIM) is specifically found in East Asia. To explain some epidemiological discrepancies between Asian and Western countries, we analyzed a silent single nucleotide polymorphism (SNP) in exon 5 (c465C T)
Autor:
Spencer B. Gibson, James B. Johnston, Danielle C Croucher, Barbara Sherry, Susi Snitzler, Anthea Lau, Ellen N Wei, Michelle Queau, Suzanne Trudel, David Spaner, Christine Chen, Sumeet Kakar, Lisa W. Le, Harminder Paul
Publikováno v:
Leukemialymphoma. 60(4)
Lenalidomide has anti-tumor activity in CLL but can be complicated by tumor lysis syndrome (TLS) and tumor flare (TF). In our previous study using low-dose lenalidomide in treatment-naive CLL, TLS was averted but TF remained frequent and complete res
Autor:
Michael Crump, Henry Chan, Warren Mason, John Kuruvilla, Alejandro Berlin, Normand Laperriere, Fabio Y. Moraes, Anca Prica
Publikováno v:
Leukemialymphoma. 60(2)
The precise role of radiation therapy in primary central nervous system lymphoma (PCNSL) remains controversial. We reviewed the records of all patients treated for PCNSL at our center between 2004 and 2015. A total of 103 patients treated with either
Autor:
Claire Dearden, Kim Linton, Michael Potter, John Radford, Patrick Shenjere, Kate Foley, Clare Peckitt, Ian Chau, Lia P Menasce, Mark Ethell, Catherine O'Hara, Hannah Johnson, Andrew Wotherspoon, Binnaz Yasar, David Cunningham, Ayoma D. Attygalle, Adam Gibb, Rebecca Lee, Joanna Dash, Mary Gleeson, Eliza A Hawkes, Morgan Back
Publikováno v:
Leukemialymphoma. 59(7)
We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS
Publikováno v:
Leukemialymphoma. 59(6)
Our purpose was to assess outcome of patients with early-stage, favorable (per GHSG criteria) Hodgkin Lymphoma (HL) staged with FDG-PET/CT and treated with two cycles of adriamycin, bleomycin, vincristine, and dacarbazine (ABVD) followed by PET/CT as